Artificial intelligence is reshaping private capital markets. Explore how capital concentration is changing venture capital, private equity and institutional investing.
Europe’s central banks are confronting inflation driven by geopolitics, ageing populations and structural change rather than traditional demand cycles. The same forces exposing the limits of monetary policy are reshaping healthcare systems—and creating one of the largest overlooked investment opportunities in women’s health.
Gilead and UCB deployed $3B+ on similar autoimmune drugs within days. What this pharmaceutical investment convergence signals for institutional investors tracking women’s health.
$124 trillion is transferring to women. Women’s health receives 6% of healthcare investment. These are not two separate facts. They are one investment thesis.
For private wealth professionals and the HNW clients they advise, that thesis demands a direct answer to a direct question: is women’s health actually a good investment opportunity?
7 Min Read How aging populations, rising costs, and institutional inertia quietly reshaped medicine into one of the largest sectors
7-10 Min Read Blackstone and TPG’s acquisition of Hologic isn’t just a medtech move. It’s a cultural signal. Here’s what
7-10 Min Read An investor’s view on where distribution power, evidence, and risk are quietly shifting This essay reflects a
